Testing CBP-4888 in hospitalized pregnant women with early-onset preeclampsia
Tests CBP-4888 in hospitalized women with preterm preeclampsia and their babies.
Plain-language title generated from the registry record
Registry title: A Study to Investigate the Safety, Pharmacodynamic and Pharmacokinetic Characteristics of CBP-4888 in Hospitalized Participants With Preterm Preeclampsia and Their Children up to 24 Months
Key facts
- Where
- Melbourne and Parkville, AustraliaSee the 3 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Source: NCT07282171, who can take part
Where in Australia
- Monash UniversityMelbourne, AustraliaTaking people
- Royal MelbourneMelbourne, AustraliaTaking people
- The Royal Women's HospitalParkville, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Comanche Biopharma
- Trial code
- NCT07282171
- Record updated
- 18 May 2026
- Original description
This study is a dose finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous CBP-4888 in hospitalized participants with Preterm Preeclampsia receiving Standard of Care, Expectant Management. Eligible participants are between 26 +0/7 and 35 +6/7 weeks gestational age and clinically appropriate for inpatient expectant management. Eligible participants will receive standard of care expectant management for their pregnancy with the only study interventions being one subcutaneous dose of CBP-4888.Read full original descriptionShow less
An Open-Label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Subcutaneous Doses of CBP-4888 in Hospitalized Participants With Preterm Preeclampsia Receiving Standard of Care, Expectant Management
This study is a dose finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous CBP-4888 in hospitalized participants with Preterm Preeclampsia receiving Standard of Care, Expectant Management. Eligible participants are between 26 +0/7 and 35 +6/7 weeks gestational age and clinically appropriate for inpatient expectant management. Eligible participants will receive standard of care expectant management for their pregnancy with the only study interventions being one subcutaneous dose of CBP-4888.
Participants will:
* receive a single subcutaneous injection dose of CBP-4888 and will be followed through delivery and for 42 days (+14 days) after delivery. Participants will be followed through 6 weeks post delivery. * Infants will be evaluated immediately postpartum and then followed through 24 months of age with standard infant and pediatric assessments with phone calls made to parents.
Inclusion: Hospitalized with a hypertensive disorder of pregnancy (preeclampsia) defined by elevated blood pressure after 20 weeks gestation with proteinuria or, in the absence of proteinuria, with evidence of organ dysfunction (e.g., thrombocytopenia, renal insufficiency, or impaired liver function), and expected to remain hospitalized through delivery; The subject has given written consent to participate in the study; Pregnant participants aged 18 to 45 years of age; Gestational age at Day 1 between 26 weeks 0/7 days and 35 weeks 6/7 days; Deemed clinically stable and suitable for expectant management for at least 72 hours post CBP-4888 administration; The woman carries a singleton pregnancy; Anticipate that hospitalization will continue through delivery.
Exclusion: Use of another investigational drug within 30 days prior to study entry; Placenta previa, abruption, accreta, or persistent unexplained vaginal bleeding; Maternal conditions requiring immediate delivery (e.g., severe hypertension, eclampsia, non-reassuring fetal status, pulmonary edema); Known active maternal infections considered to potentially affect placental function; Significant maternal medical conditions (e.g., HELLP syndrome, advanced kidney disease, severe cardiac disease, uncontrolled neurological disorder, lupus with nephritis/cerebritis); Any other condition that, in the investigator's judgment, poses risk to mother or fetus; Fetal growth restriction (<3rd percentile, or <10th percentile with abnormal Doppler) or known major chromosomal/genetic abnormalities.